Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-02-07 00:00:00 ET · period of report 2023-02-03 · accession 0001883850-23-000037 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-07 | 2023-02-03 | REGN | Fenimore Christopher R. | SVP Ctrl | F - Tax | $774.29 | -3,286 | 20.3K | -14% | -$2.54M |
| D | 2023-02-07 | 2023-02-03 | REGN | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $270.43 | +5,000 | 23.6K | +27% | +$1.35M |
| D | 2023-02-07 | 2023-02-03 | REGN | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $0.00 | -5,000 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-03 | F | D | 3,286 | $774.29 | 20,295 | D | — | — | |
| 2 | Common | Common Stock | 2023-02-03 | M | A | 5,000 | $270.43 | 23,581 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-02-03 | M | D | 5,000 | $0.00 | 0 | D | $270.43 · — to 2023-12-13 | 5,000 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |